MX2010003630A - Administracion sostenida de analogos de compstatina desde geles. - Google Patents
Administracion sostenida de analogos de compstatina desde geles.Info
- Publication number
- MX2010003630A MX2010003630A MX2010003630A MX2010003630A MX2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained delivery
- gels
- compstatin analogs
- compstatin analog
- compstatin
- Prior art date
Links
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 title abstract 3
- 230000002459 sustained effect Effects 0.000 title abstract 2
- 239000000499 gel Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000006193 liquid solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97691907P | 2007-10-02 | 2007-10-02 | |
| US2646008P | 2008-02-05 | 2008-02-05 | |
| PCT/US2008/078593 WO2009046198A2 (en) | 2007-10-02 | 2008-10-02 | Sustained delivery of compstatin analogs from gels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010003630A true MX2010003630A (es) | 2010-04-21 |
Family
ID=40526950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010003630A MX2010003630A (es) | 2007-10-02 | 2008-10-02 | Administracion sostenida de analogos de compstatina desde geles. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110182877A1 (enExample) |
| EP (1) | EP2207530A4 (enExample) |
| JP (1) | JP2010540654A (enExample) |
| KR (2) | KR20100094453A (enExample) |
| CN (1) | CN101854916A (enExample) |
| AU (1) | AU2008308657A1 (enExample) |
| BR (1) | BRPI0817524A2 (enExample) |
| CA (1) | CA2701470A1 (enExample) |
| MX (1) | MX2010003630A (enExample) |
| RU (1) | RU2505311C2 (enExample) |
| WO (1) | WO2009046198A2 (enExample) |
| ZA (1) | ZA201002365B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US20110092446A1 (en) * | 2007-07-20 | 2011-04-21 | Cedric Francois | Compositions and methods for treatment of trauma |
| EP2278987A4 (en) * | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
| TWI492769B (zh) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| US9107822B2 (en) | 2010-09-03 | 2015-08-18 | Santen Sas | Water-in oil type emulsion for treating a disease of the eye |
| EP2425814B1 (en) | 2010-09-03 | 2013-06-19 | Novagali Pharma S.A. | A water-in-oil type emulsion for treating a disease of the eye |
| NZ607103A (en) | 2010-09-03 | 2015-09-25 | Santen Sas | A water-in-oil type emulsion for treating a disease of the eye |
| US10125171B2 (en) | 2011-05-11 | 2018-11-13 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
| BR112013033272A2 (pt) | 2011-06-22 | 2020-11-10 | Apellis Pharmaceuticals, Inc. | composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos |
| WO2014028861A1 (en) * | 2012-08-17 | 2014-02-20 | Apellis Pharmaceuticals, Inc. | Detection of high risk drusen |
| CN110882376B (zh) | 2012-11-15 | 2023-10-20 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法 |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| US9940683B2 (en) | 2013-07-31 | 2018-04-10 | Elwha Llc | Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period |
| US20150039337A1 (en) * | 2013-07-31 | 2015-02-05 | Elwha Llc | Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period |
| EP2918262B1 (en) | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
| JP6432954B2 (ja) | 2014-06-12 | 2018-12-05 | ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 補体活性の変調 |
| CA2970502A1 (en) * | 2014-12-12 | 2016-06-16 | The Schepens Eye Research Institute, Inc. | Gdnf induction for the treatment of retinal disorders |
| SI3250230T1 (sl) | 2015-01-28 | 2022-01-31 | Ra Pharmaceuticals, Inc. | Modulatorji aktivnosti komplementa |
| EP3095440B1 (en) | 2015-05-19 | 2020-01-15 | PLS-Design GmbH | Antigen-specific immunotherapy using tolerizing liposomes |
| HK1259307A1 (zh) | 2015-10-07 | 2019-11-29 | 阿佩利斯制药有限公司 | 给药方案 |
| AU2016370210A1 (en) * | 2015-12-16 | 2018-06-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| RU2661621C2 (ru) * | 2016-12-19 | 2018-07-17 | Александр Николаевич Епихин | Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций |
| KR20240135047A (ko) | 2017-04-07 | 2024-09-10 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| AU2018386304B2 (en) * | 2017-12-15 | 2023-12-07 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| ES2373649T3 (es) * | 2002-09-20 | 2012-02-07 | The Trustees Of The University Of Pennsylvania | Análogos de compstatina con actividad mejorada. |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| AU2006302212B2 (en) * | 2005-10-08 | 2012-12-20 | Apellis Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| PT1960422E (pt) * | 2005-11-28 | 2012-08-16 | Univ Pennsylvania | Análogos de compstatina potentes |
| JP2009521506A (ja) * | 2005-12-22 | 2009-06-04 | アルコン リサーチ， リミテッド | 補体因子ｈの危険である改変体をもつ患者における年齢による斑状変性の予防および処置のためのｃ３コンバターゼインヒビター |
| US20070196367A1 (en) * | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| US8580735B2 (en) * | 2007-02-05 | 2013-11-12 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
-
2008
- 2008-10-02 KR KR1020107008703A patent/KR20100094453A/ko not_active Ceased
- 2008-10-02 US US12/681,392 patent/US20110182877A1/en not_active Abandoned
- 2008-10-02 WO PCT/US2008/078593 patent/WO2009046198A2/en not_active Ceased
- 2008-10-02 BR BRPI0817524A patent/BRPI0817524A2/pt not_active IP Right Cessation
- 2008-10-02 KR KR1020157016589A patent/KR20150080007A/ko not_active Ceased
- 2008-10-02 AU AU2008308657A patent/AU2008308657A1/en not_active Abandoned
- 2008-10-02 RU RU2010113513/15A patent/RU2505311C2/ru not_active IP Right Cessation
- 2008-10-02 CA CA2701470A patent/CA2701470A1/en not_active Abandoned
- 2008-10-02 MX MX2010003630A patent/MX2010003630A/es unknown
- 2008-10-02 CN CN200880115155A patent/CN101854916A/zh active Pending
- 2008-10-02 EP EP08836209.0A patent/EP2207530A4/en not_active Withdrawn
- 2008-10-02 JP JP2010528129A patent/JP2010540654A/ja active Pending
-
2010
- 2010-04-01 ZA ZA2010/02365A patent/ZA201002365B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2505311C2 (ru) | 2014-01-27 |
| CN101854916A (zh) | 2010-10-06 |
| JP2010540654A (ja) | 2010-12-24 |
| ZA201002365B (en) | 2010-12-29 |
| US20110182877A1 (en) | 2011-07-28 |
| RU2010113513A (ru) | 2011-11-10 |
| KR20100094453A (ko) | 2010-08-26 |
| EP2207530A2 (en) | 2010-07-21 |
| CA2701470A1 (en) | 2009-04-09 |
| KR20150080007A (ko) | 2015-07-08 |
| WO2009046198A3 (en) | 2009-07-16 |
| WO2009046198A2 (en) | 2009-04-09 |
| AU2008308657A1 (en) | 2009-04-09 |
| EP2207530A4 (en) | 2013-09-11 |
| BRPI0817524A2 (pt) | 2017-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010003630A (es) | Administracion sostenida de analogos de compstatina desde geles. | |
| Zhang et al. | Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates | |
| GB2471304B (en) | A pre-filled syringe or autoinjector | |
| WO2012054500A3 (en) | Compositions for drug administration | |
| PH12013500741A1 (en) | Peptide-based in vivo sirna delivery system | |
| MX2012006998A (es) | Composicion antitranspirante/desodorante anhidra liquida. | |
| EP4403197A3 (en) | Injectable formulations for organ augmentation | |
| MX2014007233A (es) | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. | |
| MX2010005272A (es) | Dispensador de gel dosificado. | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| PT2222669E (pt) | Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p) | |
| PH12015500850A1 (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
| MX2014002062A (es) | Nanoparticulas de peptido y usos de las mismas. | |
| TN2012000261A1 (en) | Aerosol formulation for copd | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| AR074046A1 (es) | Envase para la administracion iontoforetica de un farmaco | |
| ZA200807027B (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
| AR081875A1 (es) | Utilizacion de la asociacion de un inhibidor de la corriente sinusal iy de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca | |
| MX365599B (es) | Moleculas de transporte especificas de proteoglicano c4s. | |
| EP1758923B8 (en) | Peptide substance restoring myocardium function | |
| MX2010001429A (es) | Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco. | |
| SA112340077B1 (ar) | نظام إيصال siRNA داخل الكائن الحي يعتمد على الببتيدات | |
| UA93515C2 (ru) | Медикаментозное средство ha ochobe рутина | |
| PE20080268A1 (es) | Composicion farmaceutica que comprende un compuesto peptidico agonista de trombopoyetina (tpo) |